Verification evidence is still being completed.
PDF / print export
Diaprost AB
Lund, Sweden
- Verified lead
- Johan Drott
- Lead status
- STATUS: VERIFIED APRIL 2026
- Leadership verification
- Founder and Chief Executive Officer
- 2026 technical specialization
- Humanized Antibody Theranostics, Prostate Cancer Radioimmunotherapy, and Preclinical Antibody Licensing
- Review cycle
- 24 April 2026
- Full address
- Scheeletorget 1, 223 63 Lund, Sweden
- Site coordinates
- Verification evidence is still being completed.
- Editorial review
- Memel Biotech editorial review
- Official leadership source
- Diaprost team page naming Johan Drott as Founder and CEO.
- Editorial note
- Lund theranostic antibody developer with a named founder-CEO, a disclosed Radiopharm Theranostics license, and a focused prostate-cancer pipeline around hu5A10 and hu11B6.
Humanized Antibody Theranostics, Prostate Cancer Radioimmunotherapy, and Preclinical Antibody Licensing
Public leadership disclosure on company site, Documented licensing deal with Radiopharm Theranostics, Medicon Village membership listing
Lund theranostic antibody developer with a named founder-CEO, a disclosed Radiopharm Theranostics license, and a focused prostate-cancer pipeline around hu5A10 and hu11B6.
Review coverage
Leadership
Facility
Certifications
Capabilities
Partners
Sources
Quality
Editorial verificationMemel Biotech directory review sign-off
Report generated02 Jun 2026, 01:40
Company profile · Lund, Sweden
Diaprost AB
Humanized Antibody Theranostics, Prostate Cancer Radioimmunotherapy, and Preclinical Antibody Licensing · Preclinical to early-clinical
Lund theranostic antibody developer with a named founder-CEO, a disclosed Radiopharm Theranostics license, and a focused prostate-cancer pipeline around hu5A10 and hu11B6.
- Lead
- Johan Drott (verified ↗)
- Address
- Scheeletorget 1, 223 63 Lund, Sweden (source ↗)
- Compliance
- Not yet on record
- Last reviewed
- 24 Apr 2026 (1mo ago)
- Scale
- Preclinical to early-clinical
- Capabilities
- Humanized Antibody Discovery · Radiolabeled Theranostic Design · Out-Licensing and Partnering
- Founded
- 2013
- Headcount
- 1-10
- Company page (open ↗)
Clinical profileSTATUS: VERIFIED APRIL 2026
Johan Drott
Founder and Chief Executive Officer
Full addressScheeletorget 1, 223 63 Lund, Sweden
Site coordinatesVerification evidence is still being completed.
Review cycle24 April 2026
Physical site source
Medicon Village member directory page listing Diaprost AB at Scheeletorget 1.
Open sourcePreclinical to early-clinical
Lund, Sweden. Humanized Antibody Theranostics, Prostate Cancer Radioimmunotherapy, and Preclinical Antibody Licensing. Review completed on 24 Apr 2026.
Swedish Medical Products Agency and partner-controlled clinical development
Public leadership disclosure on company site, Documented licensing deal with Radiopharm Theranostics, Medicon Village membership listing
Humanized Antibody Theranostics, Prostate Cancer Radioimmunotherapy, and Preclinical Antibody Licensing
Lund theranostic antibody developer with a named founder-CEO, a disclosed Radiopharm Theranostics license, and a focused prostate-cancer pipeline around hu5A10 and hu11B6.
Editorial note
Diaprost is a Medicon Village-based R&D biotech with a named CEO, a documented licensing deal with Radiopharm Theranostics for hu5A10, and a clear prostate-cancer theranostic narrative built around humanized antibodies and radionuclide partners.
FULL TRUST REVIEW COMPLETE
Shown only when all seven trust checks are fully mapped in the directory.
Current review cycleApril 2026
Capabilities
Core capabilities
Primary declared technical activities and areas of operating focus.
Humanized Antibody Discovery
Radiolabeled Theranostic Design
Out-Licensing and Partnering
Verification source dossier
Verification source dossier
Official source set used to support leadership, physical-site, certification, and watch-note evidence.
Infrastructure
Declared infrastructure
Antibody engineering platforms
Preclinical in vivo prostate-cancer models
Partner radiolabeling (Lu-177 and alpha-emitter)
Regulatory posture
Quality system coverage
GMP / GLP / ISO-13485 / FDA-Inspected are global quality-system standards. "Verified active" means the directory confirmed the certification is current; "Review in progress" means the cert status is currently being re-verified.
- GMP
- REVIEW IN PROGRESS 2026
- GLP
- REVIEW IN PROGRESS 2026
- ISO-13485
- REVIEW IN PROGRESS 2026
- FDA-Inspected
- REVIEW IN PROGRESS 2026
Verification history
Verification history
24 Apr 2026: Executive identity confirmed via official management disclosure.
24 Apr 2026: Full trust review completed.
FAQ
Frequently asked questions
- Where is Diaprost AB located?
- Diaprost AB operates from Scheeletorget 1, 223 63 Lund, Sweden, Lund, Sweden.
- Who runs Diaprost AB?
- Diaprost AB is led by Johan Drott, Founder and Chief Executive Officer. Verified 24 Apr 2026.
- What does Diaprost AB do?
- Lund theranostic antibody developer with a named founder-CEO, a disclosed Radiopharm Theranostics license, and a focused prostate-cancer pipeline around hu5A10 and hu11B6. Core capabilities: Humanized Antibody Discovery, Radiolabeled Theranostic Design, Out-Licensing and Partnering.
Editorial context
Related technical briefs
Briefs that name Lund as a covered market or city.